AbbVie Q2 Beats with $16.99B Revenue and $3.65 EPS but Cuts Guidance on $10.9 Billion Apogee Acquisition

AbbVie delivered a strong Q2 earnings beat with revenue of $16.99 billion and adjusted EPS of $3.65 surpassing analyst estimates, but the pharmaceutical giant simultaneously lowered its full-year guidance as the accounting impact of its $10.9 billion acquisition of Apogee Therapeutics introduces near-term EPS dilution.

• AbbVie Q2 revenue hit $16.99 billion and adjusted EPS reached $3.65, both above Wall Street estimates on strength in Skyrizi and Rinvoq immunology sales
• Full-year EPS guidance was lowered to reflect the dilutive accounting impact of the $10.9 billion Apogee Therapeutics acquisition closed during the quarter
• Apogee's bispecific antibody pipeline addresses atopic dermatitis and autoimmune indications, extending AbbVie's immunology franchise beyond the current Skyrizi and Rinvoq revenue base

AbbVie's Q2 operational performance was impressive: revenue of $16.99 billion and adjusted EPS of $3.65 both cleared analyst consensus, driven by continued market share gains for Skyrizi (risankizumab) in psoriasis and IBD, and Rinvoq (upadacitinib) expanding across rheumatoid arthritis, atopic dermatitis, and Crohn's disease indications. The immunology franchise continues to demonstrate that AbbVie's post-Humira transition strategy—which looked uncertain three years ago—is executing well on commercial metrics.

The guidance reduction following a Q2 beat creates the classic investor tension inherent in large-scale pharma M&A. The $10.9 billion Apogee deal brings acquisition accounting charges—including purchase price allocations that create intangible asset amortization, deal financing costs, and integration expenses—that weigh on near-term adjusted EPS even under a methodology that aims to strip out one-time items. Investors must determine whether these short-term dilutive mechanics are offset by the long-term value of Apogee's bispecific antibody pipeline targeting a large autoimmune patient population.

Apogee's therapeutic focus on next-generation atopic dermatitis treatments positions AbbVie in a market where Dupixent (dupilumab, Sanofi/Regeneron) has demonstrated the commercial potential of biologic therapies. Bispecific antibodies offer the theoretical advantage of dual-target engagement that could achieve superior efficacy in difficult-to-treat patients. The $10.9 billion acquisition price reflects this competitive premium and the expectation of differentiated clinical performance in Phase 3 trials that will determine whether the investment thesis holds.

Source: GuruFocus | 2 sources